COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
NED Biosystems is a Cambridge-based clinical-stage biotech developing NED-170, a daily oral seven-component combination targeting five physiological drivers of late-stage cancers, pursuing Phase 2 via 505(b)(2).